Baseline patient characteristics: the observed values of the original baseline, i.e., the screening or baseline visit in the patient’s original study.
| Characteristics | All Exposure Population, n = 2578 |
|---|---|
| Mean age (SD), yrs | 52.5 (11.8) |
| Female, no. (%) | 2070 (80.3) |
| Race, no. (%) | |
| White | 2057 (79.8) |
| Black | 114 (4.4) |
| Hispanic | 319 (12.4) |
| Other | 88 (3.4) |
| Rheumatoid factor-positive, no. (%) | 1956 (75.9) |
| Mean RA disease duration (SD), yrs (3 patients not included) | 10.1 (8.3) |
| Mean no. (SD) previous biologic and nonbiologic DMARD (excluding MTX) | 2.6 (2.0) |
| Mean no. (SD) previous biologic DMARD | 0.8 (1.0) |
| Previously treated with TNF inhibitor, % | 53 |
| Baseline use of concomitant corticosteroids, % | 36 |
| Baseline Disease Activity* | Patients |
| Mean DAS28-ESR (SD) | 6.65 (1.0)** |
| Mean SJC (66 joints) (SD) | 20.4 (11.2) |
| Mean TJC (68 joints) (SD) | 31.6 (15.5) |
↵* n = 1923 patients; data for 655 pateints from SUNRISE and SIERRA studies were not included.
↵** n = 1920 patients. DMARD: disease-modifying antirheumatic drug; MTX: methotrexate; TNF: tumor necrosis factor; DAS28: disease activity score in 28 joints; ESR: erythrocyte sedimentation rate; SJC: swollen joint count; TJC: tender joint count.